Supplier
Memorial Hospital for Cancer and Allied Diseases
Memorial Hospital for Cancer and Allied Diseases was paid $135.13M by Medicaid between Jan 2018 and Dec 2024, across 447 billing codes. Its largest line is G0463, Hospital outpatient clinic visit for assessment and management of a patient — 13% of everything it billed.
33Billing provider infoMEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES
NEW YORK, NY 10065
NEW YORK, NY 10065
33aNPI1700887411assigned 08/03/2005
33bProvider typePharmacy
28Total paid$135.13M
24GClaims1,316,373
24DCodes billed447
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Pharmacy providers in New York
Rank by total paid#1 of 126
Median peer was paid$2K
This provider vs. median57,338×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 20,124 | $571K | |
| 2019 | 78,880 | $5.18M | |
| 2020 | 171,034 | $13.53M | |
| 2021 | 204,623 | $16.79M | |
| 2022 | 211,649 | $17.50M | |
| 2023 | 328,080 | $39.43M | |
| 2024incomplete | 301,983 | $42.12M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 13% | 135,194 | 81,782 | $17.05M |
| J9271 | Injection, pembrolizumab, 1 mg | 11% | 2,872 | 2,184 | $15.52M |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 4.8% | 35,131 | 19,481 | $6.48M |
| J9299 | Injection, nivolumab, 1 mg | 3.5% | 1,170 | 813 | $4.76M |
| 96416 | 2.7% | 6,262 | 3,703 | $3.70M | |
| J9306 | Injection, pertuzumab, 1 mg | 2.7% | 971 | 736 | $3.68M |
| 96415 | 2.6% | 7,072 | 2,745 | $3.47M | |
| J9358 | Injection, fam-trastuzumab deruxtecan-nxki, 1 mg | 2.5% | 863 | 361 | $3.32M |
| Q5117 | Injection, trastuzumab-anns, biosimilar, (kanjinti), 10 mg | 2.2% | 1,913 | 1,381 | $2.95M |
| J2506 | Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | 2.1% | 2,356 | 1,753 | $2.84M |
| 77412 | 1.9% | 8,280 | 1,138 | $2.60M | |
| J2505 | Injection, pegfilgrastim, 6 mg | 1.8% | 1,975 | 1,407 | $2.48M |
435 more codes
| 77336 | 1.8% | 5,475 | $2.37M | |
| Q5111 | Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg | 1.7% | 1,777 | $2.31M |
| 80053 | Comprehensive metabolic panel | 1.7% | 89,996 | $2.29M |
| 77386 | 1.6% | 10,969 | $2.18M | |
| J9348 | Injection, naxitamab-gqgk, 1 mg | 1.4% | 72 | $1.91M |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.3% | 9,194 | $1.81M |
| Q5107 | Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg | 1.3% | 2,002 | $1.69M |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | 1.2% | 13,655 | $1.68M |
| 36430 | 1.2% | 3,497 | $1.58M | |
| 78815 | Positron emission tomography (PET) for limited area imaging | 1.1% | 4,361 | $1.49M |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | 1.1% | 5,140 | $1.44M |
| J9264 | Injection, paclitaxel protein-bound particles, 1 mg | <1% | 864 | $1.28M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 8,027 | $1.22M |
| 77373 | <1% | 1,664 | $1.17M | |
| 96367 | <1% | 9,899 | $1.15M | |
| 77387 | <1% | 3,118 | $1.07M | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 4,784 | $1.04M |
| P9040 | Red blood cells, leukocytes reduced, irradiated, each unit | <1% | 2,287 | $1.02M |
| 78816 | <1% | 1,614 | $995K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 3,923 | $978K |
| 77300 | <1% | 2,407 | $974K | |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | <1% | 2,515 | $933K |
| J0897 | Injection, denosumab, 1 mg | <1% | 1,458 | $908K |
| J9144 | Injection, daratumumab, 10 mg and hyaluronidase-fihj | <1% | 325 | $877K |
| P9073 | Platelets, pheresis, pathogen-reduced, each unit | <1% | 1,245 | $820K |
| 77334 | <1% | 2,736 | $814K | |
| 38222 | <1% | 1,521 | $789K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 9,050 | $740K |
| J0185 | Injection, aprepitant, 1 mg | <1% | 7,603 | $719K |
| 36591 | <1% | 26,376 | $716K | |
| J2796 | Injection, romiplostim, 10 micrograms | <1% | 794 | $650K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 3,714 | $641K |
| J9263 | Injection, oxaliplatin, 0.5 mg | <1% | 2,475 | $639K |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 13,629 | $553K |
| 36415 | Collection of venous blood by venipuncture | <1% | 77,743 | $550K |
| 36561 | <1% | 416 | $534K | |
| J9305 | Injection, pemetrexed, not otherwise specified, 10 mg | <1% | 350 | $516K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 11,274 | $511K |
| 77385 | <1% | 2,513 | $477K | |
| 86901 | <1% | 11,772 | $475K | |
| J9316 | Injection, pertuzumab, trastuzumab, and hyaluronidase-zzxf, per 10 mg | <1% | 179 | $440K |
| Q5115 | Injection, rituximab-abbs, biosimilar, (truxima), 10 mg | <1% | 167 | $439K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 18,436 | $435K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 52,965 | $432K |
| 86850 | <1% | 12,832 | $426K | |
| 88185 | <1% | 3,981 | $415K | |
| J9206 | Injection, irinotecan, 20 mg | <1% | 3,970 | $406K |
| 77290 | <1% | 976 | $378K | |
| 72197 | <1% | 1,844 | $377K | |
| J9395 | Injection, fulvestrant, 25 mg | <1% | 442 | $365K |
| 72156 | <1% | 1,737 | $343K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 8,366 | $326K |
| 19301 | <1% | 169 | $325K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 66,125 | $307K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 6,439 | $302K |
| G0383 | Level 4 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 2,003 | $293K |
| 71250 | <1% | 3,083 | $280K | |
| 96411 | <1% | 9,611 | $276K | |
| 81455 | <1% | 855 | $274K | |
| 77301 | <1% | 1,242 | $259K | |
| 74183 | <1% | 1,823 | $256K | |
| 96409 | <1% | 5,019 | $250K | |
| J9070 | Cyclophosphamide, 100 mg | <1% | 1,601 | $248K |
| 77338 | <1% | 1,245 | $247K | |
| 96417 | <1% | 10,222 | $243K | |
| 96402 | <1% | 4,702 | $235K | |
| J2353 | Injection, octreotide, depot form for intramuscular injection, 1 mg | <1% | 98 | $228K |
| 70543 | <1% | 854 | $220K | |
| 86900 | <1% | 11,775 | $219K | |
| 52000 | <1% | 176 | $215K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 5,924 | $208K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 13,361 | $206K |
| 77280 | <1% | 422 | $205K | |
| J9045 | Injection, carboplatin, 50 mg | <1% | 2,708 | $201K |
| 76536 | <1% | 2,084 | $192K | |
| 87497 | <1% | 4,536 | $192K | |
| 77001 | <1% | 666 | $192K | |
| 85097 | <1% | 1,922 | $191K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 411 | $186K |
| Q2050 | Injection, doxorubicin hydrochloride, liposomal, not otherwise specified, 10 mg | <1% | 299 | $183K |
| J9173 | Injection, durvalumab, 10 mg | <1% | 25 | $179K |
| P9037 | Platelets, pheresis, leukocytes reduced, irradiated, each unit | <1% | 352 | $178K |
| 72158 | <1% | 1,692 | $175K | |
| 45330 | <1% | 240 | $171K | |
| 72157 | <1% | 1,604 | $164K | |
| 88184 | <1% | 3,280 | $164K | |
| 70491 | <1% | 1,253 | $164K | |
| 88307 | <1% | 2,151 | $162K | |
| J0640 | Injection, leucovorin calcium, per 50 mg | <1% | 4,909 | $162K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 8,427 | $157K |
| 88360 | <1% | 2,456 | $156K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 2,589 | $151K |
| 87799 | <1% | 4,408 | $140K | |
| G0382 | Level 3 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 916 | $139K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 10,570 | $139K |
| 93970 | <1% | 297 | $139K | |
| J9355 | Injection, trastuzumab, excludes biosimilar, 10 mg | <1% | 287 | $137K |
| 76937 | <1% | 732 | $137K | |
| J9201 | Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | <1% | 2,914 | $135K |
| J1561 | Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg | <1% | 135 | $134K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 4,675 | $134K |
| 77332 | <1% | 265 | $129K | |
| 77049 | <1% | 553 | $127K | |
| Q5101 | Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram | <1% | 1,003 | $126K |
| 80076 | <1% | 9,665 | $125K | |
| 36592 | <1% | 5,252 | $124K | |
| 19281 | <1% | 86 | $122K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 2,078 | $121K |
| 77065 | Tomosynthesis, mammo | <1% | 1,603 | $117K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 5,632 | $112K |
| 77295 | <1% | 576 | $110K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 3,274 | $104K |
| J1569 | Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | <1% | 58 | $100K |
| G0384 | Level 5 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 617 | $95K |
| 78802 | <1% | 238 | $95K | |
| 88342 | <1% | 2,749 | $94K | |
| 92250 | <1% | 1,884 | $94K | |
| 96401 | <1% | 2,391 | $94K | |
| J9203 | Injection, gemtuzumab ozogamicin, 0.1 mg | <1% | 315 | $94K |
| 88341 | <1% | 2,051 | $92K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 124 | $87K |
| 72195 | <1% | 349 | $87K | |
| 38220 | <1% | 131 | $82K | |
| J9000 | Injection, doxorubicin hydrochloride, 10 mg | <1% | 2,165 | $82K |
| 19083 | <1% | 59 | $82K | |
| 78195 | <1% | 186 | $82K | |
| 86923 | <1% | 2,371 | $81K | |
| 85027 | <1% | 13,285 | $80K | |
| 92134 | <1% | 1,032 | $78K | |
| 36590 | <1% | 85 | $77K | |
| 84439 | <1% | 7,393 | $76K | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 4,150 | $74K |
| 38525 | <1% | 109 | $72K | |
| 88237 | <1% | 854 | $71K | |
| 96368 | <1% | 3,723 | $71K | |
| 96377 | <1% | 2,974 | $71K | |
| 77080 | <1% | 1,219 | $70K | |
| C2638 | Brachytherapy source, stranded, iodine-125, per source | <1% | 84 | $70K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 293 | $68K |
| OP370 | <1% | 496 | $65K | |
| 76641 | <1% | 1,508 | $65K | |
| 87517 | <1% | 1,687 | $64K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 1,337 | $64K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 2,296 | $64K |
| J9267 | Injection, paclitaxel, 1 mg | <1% | 3,702 | $62K |
| 76942 | <1% | 366 | $61K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 453 | $60K |
| 83615 | <1% | 21,855 | $59K | |
| 83735 | <1% | 23,369 | $58K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 9,900 | $57K |
| J9035 | Injection, bevacizumab, 10 mg | <1% | 206 | $57K |
| 81445 | <1% | 867 | $52K | |
| J9171 | Injection, docetaxel, 1 mg | <1% | 382 | $48K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,757 | $47K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 4,941 | $47K |
| J9190 | Injection, fluorouracil, 500 mg | <1% | 8,602 | $47K |
| 96450 | <1% | 62 | $46K | |
| 76642 | <1% | 1,284 | $43K | |
| 97161 | <1% | 402 | $42K | |
| J1610 | Injection, glucagon hydrochloride, per 1 mg | <1% | 606 | $41K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 511 | $38K |
| 84153 | <1% | 2,591 | $38K | |
| 82378 | <1% | 6,478 | $38K | |
| 97116 | <1% | 964 | $38K | |
| Q5108 | Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg | <1% | 41 | $38K |
| 80061 | Lipid panel | <1% | 2,561 | $37K |
| C1788 | Port, indwelling (implantable) | <1% | 330 | $37K |
| 88112 | <1% | 796 | $37K | |
| 77790 | <1% | 136 | $36K | |
| J2820 | Injection, sargramostim (gm-csf), 50 mcg | <1% | 380 | $36K |
| J9370 | Vincristine sulfate, 1 mg | <1% | 1,307 | $36K |
| 77066 | Tomosynthesis, mammo | <1% | 600 | $36K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 11,887 | $36K |
| 38900 | <1% | 85 | $36K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 159 | $35K |
| 84432 | <1% | 1,647 | $35K | |
| 82784 | <1% | 4,215 | $34K | |
| 87507 | <1% | 407 | $34K | |
| 85610 | <1% | 12,232 | $34K | |
| 84100 | <1% | 16,363 | $34K | |
| 86353 | <1% | 938 | $34K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 4,031 | $33K |
| 74178 | <1% | 597 | $32K | |
| 84403 | <1% | 1,860 | $32K | |
| 76770 | <1% | 103 | $32K | |
| 97162 | <1% | 204 | $30K | |
| 90686 | <1% | 1,420 | $29K | |
| 81450 | <1% | 391 | $27K | |
| 94010 | <1% | 348 | $26K | |
| A9582 | Iodine i-123 iobenguane, diagnostic, per study dose, up to 15 millicuries | <1% | 141 | $26K |
| J2997 | Injection, alteplase recombinant, 1 mg | <1% | 170 | $26K |
| 88262 | <1% | 318 | $25K | |
| 85730 | <1% | 5,203 | $25K | |
| 88271 | <1% | 470 | $24K | |
| 77370 | <1% | 65 | $24K | |
| 92018 | <1% | 82 | $23K | |
| OP710 | <1% | 165 | $23K | |
| G0378 | Hospital observation service, per hour | <1% | 213 | $22K |
| 76098 | <1% | 115 | $22K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 572 | $21K |
| 78832 | <1% | 243 | $21K | |
| 0002A | <1% | 768 | $21K | |
| 84702 | <1% | 1,422 | $19K | |
| 86769 | <1% | 925 | $19K | |
| 76377 | <1% | 1,664 | $18K | |
| 81162 | <1% | 44 | $18K | |
| 96376 | <1% | 1,640 | $18K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 9,139 | $18K |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 4,593 | $17K |
| 73720 | <1% | 54 | $17K | |
| 0001A | <1% | 806 | $17K | |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 442 | $16K |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 3,685 | $16K |
| 81206 | <1% | 145 | $16K | |
| 81378 | <1% | 143 | $16K | |
| 83970 | <1% | 367 | $16K | |
| 93356 | <1% | 708 | $15K | |
| J9060 | Injection, cisplatin, powder or solution, 10 mg | <1% | 1,401 | $15K |
| 82728 | <1% | 2,436 | $15K | |
| 77012 | <1% | 80 | $15K | |
| 84703 | <1% | 3,877 | $15K | |
| 86334 | <1% | 2,165 | $15K | |
| 10005 | <1% | 30 | $15K | |
| 86300 | <1% | 2,379 | $15K | |
| 36593 | <1% | 104 | $15K | |
| 86304 | <1% | 2,958 | $14K | |
| 88275 | <1% | 447 | $14K | |
| 85045 | <1% | 6,392 | $14K | |
| 82024 | <1% | 269 | $13K | |
| 86355 | <1% | 376 | $13K | |
| 82670 | <1% | 495 | $13K | |
| 94729 | <1% | 431 | $13K | |
| 10021 | <1% | 28 | $13K | |
| 31575 | <1% | 107 | $13K | |
| 86356 | <1% | 541 | $12K | |
| 83883 | <1% | 2,155 | $12K | |
| 81003 | <1% | 5,231 | $12K | |
| C8957 | Intravenous infusion for therapy/diagnosis; initiation of prolonged infusion (more than 8 hours), requiring use of portable or implantable pump | <1% | 50 | $12K |
| 82105 | <1% | 1,818 | $12K | |
| 82248 | <1% | 4,655 | $12K | |
| 83001 | <1% | 961 | $11K | |
| 83002 | <1% | 1,133 | $11K | |
| 81267 | <1% | 408 | $11K | |
| J3489 | Injection, zoledronic acid, 1 mg | <1% | 129 | $11K |
| 82607 | <1% | 1,159 | $11K | |
| 81301 | <1% | 86 | $11K | |
| 88325 | <1% | 362 | $11K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 437 | $10K |
| 86360 | <1% | 447 | $10K | |
| 88333 | <1% | 713 | $10K | |
| 82962 | <1% | 5,636 | $10K | |
| 88311 | <1% | 1,013 | $9K | |
| 88108 | <1% | 206 | $9K | |
| 0004A | <1% | 249 | $9K | |
| J9209 | Injection, mesna, 200 mg | <1% | 229 | $9K |
| 86359 | <1% | 448 | $9K | |
| J9075 | Injection, cyclophosphamide, not otherwise specified, 5 mg | <1% | 111 | $9K |
| 87040 | <1% | 1,417 | $9K | |
| 86704 | <1% | 2,724 | $8K | |
| 84165 | <1% | 2,256 | $8K | |
| 87340 | <1% | 2,809 | $8K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,167 | $8K |
| 92285 | <1% | 140 | $8K | |
| 88365 | <1% | 166 | $8K | |
| 80197 | <1% | 807 | $8K | |
| 82533 | <1% | 642 | $7K | |
| 86357 | <1% | 374 | $7K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 13,291 | $7K |
| 81268 | <1% | 46 | $7K | |
| 84550 | <1% | 3,343 | $7K | |
| 86141 | <1% | 1,925 | $7K | |
| 83880 | <1% | 282 | $7K | |
| 93971 | <1% | 199 | $7K | |
| J1442 | Injection, filgrastim (g-csf), excludes biosimilars, 1 microgram | <1% | 334 | $7K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 12 | $7K |
| 90677 | <1% | 129 | $7K | |
| 82550 | <1% | 1,449 | $6K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 2,835 | $6K |
| 92567 | <1% | 72 | $6K | |
| 86803 | <1% | 1,507 | $5K | |
| A9573 | Injection, gadopiclenol, 1 ml | <1% | 897 | $5K |
| 96522 | <1% | 141 | $5K | |
| 86800 | <1% | 914 | $5K | |
| 92201 | <1% | 695 | $5K | |
| 87088 | <1% | 1,728 | $5K | |
| 83690 | <1% | 1,926 | $5K | |
| A4648 | Tissue marker, implantable, any type, each | <1% | 392 | $5K |
| 0003A | <1% | 135 | $5K | |
| 86301 | <1% | 1,187 | $5K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 976 | $5K |
| 94726 | <1% | 26 | $5K | |
| 86870 | <1% | 89 | $4K | |
| 90671 | <1% | 95 | $4K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 66 | $4K |
| 84480 | <1% | 1,178 | $4K | |
| 90648 | <1% | 220 | $4K | |
| 86880 | <1% | 168 | $4K | |
| 76498 | <1% | 36 | $4K | |
| A9541 | Technetium tc-99m sulfur colloid, diagnostic, per study dose, up to 20 millicuries | <1% | 237 | $4K |
| 92226 | <1% | 113 | $4K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 73 | $4K |
| 81001 | <1% | 1,568 | $4K | |
| 86413 | <1% | 437 | $4K | |
| J9181 | Injection, etoposide, 10 mg | <1% | 581 | $4K |
| 90670 | <1% | 98 | $4K | |
| 91320 | <1% | 105 | $4K | |
| 92557 | <1% | 55 | $3K | |
| J9208 | Injection, ifosfamide, 1 gram | <1% | 38 | $3K |
| 81479 | Unlisted molecular pathology procedure | <1% | 32 | $3K |
| 90480 | <1% | 110 | $3K | |
| 88173 | <1% | 336 | $3K | |
| S0028 | Injection, famotidine, 20 mg | <1% | 4,172 | $3K |
| 81458 | <1% | 14 | $3K | |
| 86706 | <1% | 800 | $3K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 3,439 | $3K |
| 86787 | <1% | 496 | $3K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 32 | $3K |
| 90715 | <1% | 191 | $2K | |
| 85651 | <1% | 1,362 | $2K | |
| 92526 | <1% | 58 | $2K | |
| 82150 | <1% | 674 | $2K | |
| 82565 | <1% | 1,175 | $2K | |
| 83550 | <1% | 922 | $2K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 2,148 | $2K |
| 86765 | <1% | 308 | $2K | |
| 73552 | <1% | 116 | $2K | |
| S0080 | Injection, pentamidine isethionate, 300 mg | <1% | 447 | $2K |
| 0399T | <1% | 12 | $2K | |
| C1769 | Guide wire | <1% | 176 | $2K |
| G0008 | Administration of influenza virus vaccine | <1% | 351 | $2K |
| 90713 | <1% | 124 | $2K | |
| 96521 | <1% | 53 | $2K | |
| 87077 | <1% | 516 | $2K | |
| C1715 | Brachytherapy needle | <1% | 198 | $2K |
| 88172 | <1% | 152 | $2K | |
| 82746 | <1% | 375 | $1K | |
| 97166 | <1% | 12 | $1K | |
| J2545 | Pentamidine isethionate, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per 300 mg | <1% | 13 | $1K |
| 71045 | Radiologic examination, chest; single view | <1% | 184 | $1K |
| 0124A | <1% | 37 | $1K | |
| 73590 | <1% | 33 | $1K | |
| OP637 | <1% | 700 | $1K | |
| OP250 | <1% | 323 | $1K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 6,961 | $1K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 46 | $1K |
| 87625 | <1% | 40 | $1K | |
| 76510 | <1% | 13 | $1K | |
| 76830 | Ultrasound, transvaginal | <1% | 26 | $1K |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 445 | $1K |
| 87070 | <1% | 314 | $1K | |
| J2704 | Injection, propofol, 10 mg | <1% | 2,883 | $1K |
| 90656 | <1% | 85 | $1K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 29 | $992.62 |
| 84466 | <1% | 301 | $992.52 | |
| 84484 | <1% | 467 | $941.05 | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 18 | $926.57 |
| 80158 | <1% | 47 | $911.68 | |
| OP272 | <1% | 13 | $884.22 | |
| 86644 | <1% | 135 | $855.08 | |
| 82977 | <1% | 345 | $830.26 | |
| 87486 | <1% | 16 | $768.99 | |
| 82310 | <1% | 229 | $751.48 | |
| 90636 | <1% | 12 | $725.96 | |
| 86708 | <1% | 152 | $702.52 | |
| 84207 | <1% | 25 | $689.36 | |
| 84060 | <1% | 125 | $675.45 | |
| 87581 | <1% | 16 | $673.24 | |
| 84436 | <1% | 221 | $673.07 | |
| 88313 | <1% | 42 | $650.63 | |
| 90662 | <1% | 60 | $633.47 | |
| 88177 | <1% | 12 | $629.01 | |
| J0461 | Injection, atropine sulfate, 0.01 mg | <1% | 1,355 | $620.85 |
| 86709 | <1% | 151 | $618.83 | |
| 0663T | <1% | 64 | $576.05 | |
| 83520 | <1% | 153 | $565.82 | |
| 89051 | <1% | 203 | $538.26 | |
| 88300 | <1% | 67 | $535.15 | |
| 82570 | <1% | 267 | $532.00 | |
| 84156 | <1% | 407 | $529.42 | |
| 88309 | <1% | 12 | $525.34 | |
| 0064A | <1% | 14 | $520.00 | |
| 86790 | <1% | 127 | $516.90 | |
| 87533 | <1% | 29 | $509.29 | |
| 83605 | <1% | 291 | $492.78 | |
| J0136 | Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg | <1% | 1,805 | $461.39 |
| 83010 | <1% | 92 | $443.85 | |
| 90694 | <1% | 29 | $436.65 | |
| J9360 | Injection, vinblastine sulfate, 1 mg | <1% | 21 | $393.96 |
| 84481 | <1% | 101 | $386.10 | |
| 87205 | <1% | 238 | $365.08 | |
| 88363 | <1% | 43 | $358.36 | |
| 87186 | <1% | 159 | $341.82 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 334 | $323.63 |
| J9130 | Dacarbazine, 100 mg | <1% | 16 | $322.35 |
| 82232 | <1% | 55 | $302.90 | |
| 0031A | <1% | 18 | $293.53 | |
| C1729 | Catheter, drainage | <1% | 102 | $286.15 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,222 | $280.24 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 785 | $275.69 |
| 86780 | <1% | 52 | $248.94 | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 1,254 | $226.43 |
| J0184 | Injection, amisulpride, 1 mg | <1% | 33 | $207.60 |
| 77417 | <1% | 495 | $183.88 | |
| 82985 | <1% | 16 | $165.93 | |
| J0689 | Injection, cefazolin sodium (baxter), not therapeutically equivalent to j0690, 500 mg | <1% | 678 | $163.69 |
| J7612 | Levalbuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 0.5 mg | <1% | 163 | $161.92 |
| Q9968 | Injection, non-radioactive, non-contrast, visualization adjunct (e.g., methylene blue, isosulfan blue), 1 mg | <1% | 18 | $161.53 |
| 85385 | <1% | 50 | $120.86 | |
| 74019 | <1% | 17 | $120.15 | |
| 86705 | <1% | 73 | $92.12 | |
| 84520 | <1% | 42 | $81.35 | |
| OP270 | <1% | 14 | $80.00 | |
| 87102 | <1% | 39 | $72.49 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 151 | $71.53 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,198 | $57.30 |
| J9250 | Methotrexate sodium, 5 mg | <1% | 53 | $56.65 |
| 84270 | <1% | 12 | $52.73 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 181 | $51.48 |
| 87220 | <1% | 27 | $36.30 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 694 | $30.23 |
| J3410 | Injection, hydroxyzine hcl, up to 25 mg | <1% | 28 | $29.40 |
| 99153 | Mod sedat endo service >5yrs | <1% | 27 | $27.12 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 292 | $14.47 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | <1% | 641 | $14.06 |
| 99152 | <1% | 58 | $10.24 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 116 | $9.08 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 103 | $8.12 |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 13 | $6.00 |
| 94642 | <1% | 13 | $6.00 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 429 | $4.52 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 53 | $3.33 |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 350 | $1.94 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 64 | $1.30 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 0% | 14 | $0.00 |
| 88331 | 0% | 18 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMARTIN, KATHRYN (COO)
| Provider | Location | Paid |
|---|---|---|
| Memorial Sloan Kettering Bergen | Montvale, NJ | $187K |
| Memorial Sloan Kettering Monmouth | Middletown, NJ | $140K |
| Memorial Hospital for Cancer & Allied Diseases | Basking Ridge, NJ | $99K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.